Intellia Therapeutics logo

Intellia Therapeutics

NTLA | NASDAQ
Chart Builder DCF Calculator
$9.86
+$0.16 (+1.65%)
At close: Nov 16, 2026, 4:00 PM ET
$9.80
-$0.06 (-0.61%)
After-hours: Nov 16, 2026, 7:58 PM ET
+1.65%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
48.3
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #324/1021 (Top 32%)

Key Statistics

Market Data

Market Cap $1.38B
1D Range
9.70 10.46
52W Range
8.04 17.84

Valuation (TTM)

PE -2.94
PB 2.26
EV/EBITDA -2.71

Valuation (NTM)

Forward PE 70.63
Forward PEG 0.18
Price Target $18.50
Loading financial charts...

Profile

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered...

Sector Healthcare
Industry Biotechnology
Employees 377
IPO Date May 6, 2016
Fiscal Year January - December

Latest News

Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript

4 days ago · seekingalpha.com

Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

4 days ago · globenewswire.com

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision

10 days ago · seekingalpha.com

Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

10 days ago · zacks.com

Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

12 days ago · zacks.com

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

12 days ago · globenewswire.com

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

13 days ago · globenewswire.com

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

14 days ago · globenewswire.com

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

19 days ago · globenewswire.com

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Intellia Therapeutics Appoints Jing L. Marantz, M.D.

1 month ago · globenewswire.com

Intellia Therapeutics Appoints Jing L. Marantz, M.D.

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.91
Miss -14.18%
REV
$7.16M
Miss -26.47%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
15
Consensus
Hold
Price Target
$18.50
Upside
+87.63%
Buy (7)
Hold (6)
Sell (2)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.